Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07087054 · ClinicalTrials.gov registry record · Phase 3
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
A Phase 3 study of Carcinoid Tumor and Carcinoid Syndrome, sponsored by Crinetics Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 141
- Enrollment target
- 20
- Study locations
NCT07087054: Recruiting Phase 3 study of Carcinoid Tumor and Carcinoid Syndrome, sponsored by Crinetics Pharmaceuticals.
NCT07087054 is a Phase 3 study of Carcinoid Tumor and Carcinoid Syndrome that is actively recruiting participants, run by Crinetics Pharmaceuticals. The registered enrollment target is 141 participants, above the 81-participant average among 8 other Carcinoid Tumor trials with a reported enrollment target (74% higher). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07087054, a Phase 3 study of Carcinoid Tumor and Carcinoid Syndrome, is actively recruiting participants, sponsored by Crinetics Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 141 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumors. The purpose of this study is to continue the evaluation of the safety, efficacy, and pharmacokinetics (PK) of paltusotine in participants with carcinoid syndrome.
Primary Outcome
Treatment group difference of change from baseline to Week 12 in flushing episodes/day averaged over the 14 days prior to Week 12.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Paltusotine
Study Locations (20)
Other
- Hospital de Gastroenterologia Dr. Carlos Bonorino Udaondo - Buenos Aires
- Sanatorio Guemes - Buenos Aires
- Centro de Endocrinologia y Diabetes Dr. A. Gutman ICM - Investigaciones - Buenos Aires
- Instituto Médico Especializado Alexander Fleming - Buenos Aires
Arizona
- Banner MD Anderson Cancer Center - Gilbert
California
- Hoag Memorial Hospital Presbyterian - Newport Beach
Connecticut
- Yale University - New Haven Hospital - Yale Cancer Center - New Haven
Florida
- Moffitt Cancer Center - Tampa
Georgia
- Winshop Cancer Institute - Emory University - Atlanta
Iowa
- University of Iowa Health Care - Iowa City
Kentucky
- University of Kentucky Medical Center - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2025-11-19 |
| Est. Completion | 2030-01 |
| Phase | Phase 3 |
What NCT07087054 shows while recruiting
NCT07087054 is an interventional study that assigns participants to a tested intervention. The registered 141 participants enrollment target is mid-sized for trials with a published cap, above the 81-participant average among 8 other Carcinoid Tumor trials with a reported enrollment target (74% higher).
The record links to 9 conditions, with Carcinoid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07087054 names 20 study sites across 17 states, led by Other, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT07087054 about?
NCT07087054 is a clinical study titled "Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen". A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumors. The purpose of this study is to c...
What is the current status of trial NCT07087054?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 141 participants. The study started on 2025-11-19. Estimated completion is 2030-01.
What conditions does trial NCT07087054 study?
This clinical trial studies the following conditions: Carcinoid Tumor, Carcinoid Syndrome, Carcinoid, Carcinoid Tumor of Ileum, Carcinoid Tumor of Cecum.
What interventions are being tested in trial NCT07087054?
The interventions under investigation include: Placebo (DRUG), Paltusotine (DRUG).
Who is sponsoring clinical trial NCT07087054?
This trial is sponsored by Crinetics Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07087054 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07087054's enrollment target sits among peer trials
141 2nd of 8 the highest of 8 other Carcinoid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
RECRUITING · Phase 3
-
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
RECRUITING · Phase 2
-
An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors
ACTIVE NOT RECRUITING · Early Phase 1
-
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
COMPLETED · Phase 2
-
Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
COMPLETED · Phase 2
-
Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03042962 · 141 participants
Brain Networks in Dystonia
- NCT04378439 · 141 participants · NA
Appalachian Partnership to Reduce Disparities (Aim 2)
- NCT04775485 · 141 participants · Phase 2
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
- NCT05040360 · 141 participants · Phase 2
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI